1. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.

    Blood 128(3):360 (2016) PMID 27166358 PMCID PMC4957161

    The mechanisms underlying the maintenance of long-lasting humoral immunity are not well understood. Studies in mice indicate that plasma cells (PCs) can survive up to a lifetime, even in the absence of regeneration by B cells, implying the presence of long-lived PCs as a mechanism for long-lasti...
  2. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

    Clinical Cancer Research 22(11):2684 (2016) PMID 26819453

    Responses to therapy with chimeric antigen receptor T cells recognizing CD19 (CART19, CTL019) may vary by histology. Mantle cell lymphoma (MCL) represents a B-cell malignancy that remains incurable despite novel therapies such as the BTK inhibitor ibrutinib, and where data from CTL019 therapy ar...
  3. Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

    Blood 127(17):2131 (2016) PMID 26864341 PMCID PMC4850868

    Leukemias expressing constitutively activated mutants of ABL1 tyrosine kinase (BCR-ABL1, TEL-ABL1, NUP214-ABL1) usually contain at least 1 normal ABL1 allele. Because oncogenic and normal ABL1 kinases may exert opposite effects on cell behavior, we examined the role of normal ABL1 in leukemias i...
  4. Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.

    Blood 127(10):1287 (2016) PMID 26738536 PMCID PMC4786838

    Cutaneous T-cell lymphoma (CTCL) is characterized by proliferation of malignant T cells in a chronic inflammatory environment. With disease progression, bacteria colonize the compromised skin barrier and half of CTCL patients die of infection rather than from direct organ involvement by the mali...
  5. (13)C MRS and LC-MS Flux Analysis of Tumor Intermediary Metabolism.

    Frontiers in Oncology 6:135 (2016) PMID 27379200 PMCID PMC4908130

    We present the first validated metabolic network model for analysis of flux through key pathways of tumor intermediary metabolism, including glycolysis, the oxidative and non-oxidative arms of the pentose pyrophosphate shunt, the TCA cycle as well as its anaplerotic pathways, pyruvate-malate shu...
  6. Combined B12 and folate deficiency presenting as an aggressive hematologic malignancy.

    American Journal of Hematology 90(10):964 (2015) PMID 25720584

  7. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.

    Oncotarget 6(24):20555 (2015) PMID 26244872 PMCID PMC4653025

    Aberrant activation of Janus kinase-3 (Jak3) and its key down-stream effectors, Signal Transducer and Activator of Transcription-3 (STAT3) and STAT5, is a key feature of malignant transformation in cutaneous T-cell lymphoma (CTCL). However, it remains only partially understood how Jak3/STAT acti...
  8. Malignant T cells express lymphotoxin α and drive endothelial activation in cutaneous T cell lymphoma.

    Oncotarget 6(17):15235 (2015) PMID 25915535 PMCID PMC4558148

    Lymphotoxin α (LTα) plays a key role in the formation of lymphatic vasculature and secondary lymphoid structures. Cutaneous T cell lymphoma (CTCL) is the most common primary lymphoma of the skin and in advanced stages, malignant T cells spreads through the lymphatic to regional lymph nodes to in...
  9. Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients.

    Oncotarget 6(16):14374 (2015) PMID 25957418 PMCID PMC4546473

    CD22 is a member of the Sialic acid-binding Ig-like lectin (Siglec) family of lectins described to be exclusively present in B lymphocytes and B cell-derived neoplasms. Here, we describe a novel splice form of CD22 (designated CD22∆N), which lacks the N-terminal domain as demonstrated by exon-...
  10. IL-13 as a novel growth factor in CTCL.

    Blood 125(18):2737 (2015) PMID 25931576

  11. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.

    Anticancer Research 34(12):7207 (2014) PMID 25503151

    Mycosis fungoides (MF) is the most common variant of cutaneous T-cell lymphoma (CTCL). MF is characterized by chronic inflammation dominated by cluster of differentiation 4-positive (CD4(+)) T-cells and T helper 2 cytokines, and as the malignant T-cell clone is initially elusive, early diagnosis...
  12. STAT3 activation and infiltration of eosinophil granulocytes in mycosis fungoides.

    Anticancer Research 34(10):5277 (2014) PMID 25275020

    Eosinophil granulocytes have been implicated in anticancer immunity but recent data indicate that eosinophils can also promote cancer. Herein, we studied eosinophils in skin lesions from 43 patients with mycosis fungoides (MF). The presence of eosinophils correlated with disease stage: 78% of pa...
  13. Intravascular large B cell lymphoma presenting as a thyroid mass.

    Endocrine Pathology 25(3):359 (2014) PMID 24014041

  14. Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation.

    Blood 124(5):761 (2014) PMID 24957145 PMCID PMC4118485

    Patients with cutaneous T-cell lymphoma (CTCL) are frequently colonized with Staphylococcus aureus (SA). Eradication of SA is, importantly, associated with significant clinical improvement, suggesting that SA promotes the disease activity, but the underlying mechanisms remain poorly characterize...
  15. Validation of a diagnostic microRNA classifier in cutaneous T-cell lymphomas.

    Leukemia & Lymphoma 55(4):957 (2014) PMID 23772646

  16. Development of lymphomas containing Epstein-Barr virus after therapy with hyper-CVAD regimen.

    Clinical Lymphoma Myeloma and Leukemia 14(2):e55 (2014) PMID 24393621

  17. Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner.

    Journal of Immunology 192(6):2913 (2014) PMID 24523507 PMCID PMC3984051

    In this article, we report that cutaneous T cell lymphoma (CTCL) cells and tissues ubiquitously express the immunosuppressive cell surface protein CD80 (B7-1). CD80 expression in CTCL cells is strictly dependent on the expression of both members of the STAT5 family, STAT5a and STAT5b, as well as...
  18. Transcriptional repressor domain of MBD1 is intrinsically disordered and interacts with its binding partners in a selective manner.

    Scientific reports 4:4896 (2014) PMID 24810720 PMCID PMC4014985

    Methylation of DNA CpG sites is a major mechanism of epigenetic gene silencing and plays important roles in cell division, development and carcinogenesis. One of its regulators is the 64-residue C-terminal Transcriptional Repressor Domain (the TRD) of MBD1, which recruits several repressor prote...
  19. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF).

    Cell Cycle 13(8):1306 (2014) PMID 24621498 PMCID PMC4049967

    Skin lesions from mycosis fungoides (MF) patients display an increased expression of interleukin-15 (IL-15), IL-17F, and other cytokines implicated in inflammation and malignant cell proliferation in cutaneous T-cell lymphoma (CTCL). In the leukemic variant of CTCL, Sézary syndrome (SS), IL-2 an...
  20. Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.

    Journal of Immunology 191(12):6200 (2013) PMID 24218456 PMCID PMC3889215

    Anaplastic lymphoma kinase (ALK), physiologically expressed only by nervous system cells, displays a remarkable capacity to transform CD4(+) T lymphocytes and other types of nonneural cells. In this study, we report that activity of nucleophosmin (NPM)/ALK chimeric protein, the dominant form of ...